Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Cancer Medicine|May 13, 2021
Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysisRobert C Chick, Mark B Faries, Diane F Hale, et al.
Biorxiv : the Preprint Server for Biology|June 25, 2024
Differences in systemic immune parameters in individuals with lung cancer according to raceMitchell S von Itzstein, Jialiang Liu, Hong Mu-Mosley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2025
Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naive Advanced MelanomaAntoni Ribas, Mohammed M Milhem, Christopher J Hoimes, et al.
Melanoma Research|July 1, 2021
Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanomaAlexandra M Adams, Robert C Chick, Timothy J Vreeland, et al.
JTO Clinical and Research Reports|December 2, 2024
Racial Differences in Systemic Immune Parameters in Individuals With Lung CancerMitchell S von Itzstein, Jialiang Liu, Hong Mu-Mosley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2022
Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA TrialChung-Han Lee, Robert Motzer, Hamid Emamekhoo, et al.
The Lancet. Oncology|September 14, 2016
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trialF Stephen Hodi, Jason Chesney, Anna C Pavlick, et al.
Cancer Discovery|March 12, 2021
Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory MelanomaCara Haymaker, Daniel H Johnson, Ravi Murthy, et al.
Cancer Treatment and Research Communications|September 21, 2024
Tumor lysate particle only vaccine (TLPO) vs. Tumor lysate particle-loaded, dendritic cell vaccine (TLPLDC) to prevent recurrence in resected stage III/IV melanoma patients: Results of a phase I/IIa trialSpencer G Van Decar, Elizabeth L Carpenter, Alexandra M Adams, et al.
Lancet (London, England)|January 21, 2024
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b studyJeffrey S Weber, Matteo S Carlino, Adnan Khattak, et al.
Pageof 4